Journal
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 85, Issue 12, Pages 1426-1434Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2014-307662
Keywords
-
Categories
Funding
- NIHR Queen Square Dementia BRU
- National Health and Medical research Council of Australia (NHMRC) [1037746]
- Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Node [CE110001021]
- AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly)
- National Brain Appeal-Frontotemporal Dementia Research Fund
- Alzheimers Research UK [ARUK-Network2011-6-ICE] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10134, NF-SI-0508-10123] Funding Source: researchfish
Ask authors/readers for more resources
Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available